Lonergan, Mike, Senn, Stephen J, McNamee, Christine ORCID: 0000-0001-8763-8979, Daly, Ann K, Sutton, Robert ORCID: 0000-0001-6600-562X, Hattersley, Andrew, Pearson, Ewan and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2017)
Defining drug response for stratified medicine.
DRUG DISCOVERY TODAY, 22 (1).
pp. 173-179.
Text
Position Paper defining response clean.pdf - Author Accepted Manuscript Download (583kB) |
|
Text
Highlights.pdf - Author Accepted Manuscript Download (181kB) |
|
Text
Box 1.pdf - Author Accepted Manuscript Download (185kB) |
|
Text
Paper Figure 1.pdf - Author Accepted Manuscript Download (347kB) |
|
Text
Paper Figure2.pdf - Author Accepted Manuscript Download (99kB) |
Abstract
The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Humans, Drug Monitoring, Pharmacogenetics, Research Design, Clinical Trials as Topic, Biomarkers, Pharmacological, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions, Precision Medicine |
Depositing User: | Symplectic Admin |
Date Deposited: | 18 Nov 2016 16:03 |
Last Modified: | 19 Jan 2023 07:25 |
DOI: | 10.1016/j.drudis.2016.10.016 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3004605 |